Sunrise Oncology Partners
233 Spring Street
New York, NY 10013
P: (212) 123­1223
F: (212) 123­1224
Patient Nam e:  Mott, Elizabeth 
Patient Number: 12345678Date: 05/29/2018
Date Of Birth:   08/29/1960
Date Type Details Outcome Comment
5/1/2018 Other Therapies Synthroid 175 mcg tablet Active
5/1/2018 Other Therapies Zoloft 50 mg tablet Active
Allergies
No known allergies have been entered for this patient.
Medical and Surgical History
Hypothyroidism. Mild anxiety.
Date Type ICD­9 ICD­10 Problem Comment Status
Date Type Details Outcome Comment
9/18/2018 Surgery Tonsillectomy 1960s
Social History
Patient is married.  No history of tobacco use.  Mrs. Mott reports the following support system: lives with family. Her diet consists of 
regular meals. She indicates her daily activ
ity level as: daily activities.
Alcoh
ol Use Yes, Weekly.
Family History
Reviewed and unchanged.
Gyn History
Menarche at the age of 12. LMP more than 10 years ago.
Review
 Of Systems
Consti
tutional Symptoms: Patient reports:  no fatigue,  no weakness,  no weight loss,  no fevers,  no chills, no diaphoresis,   no night 
sweat s , no hot flashes.  exertional dyspnea, no cough
Eyes: Patient offers no eye complaints. 
Gastrointestinal : Patient offers no gastrointestinal complaints.  no nausea,  no  vomiting, no dysphagia,  no  abdominal pain,  no diarrhea,  no 
constipation
Musculoskeletal: bone pain,  no back pain,  no arthralgia  
Integumentary: Patient reports: no rash, no pruritis, no skin lesions, no dry skin
Page 1 of 2  
FOLLOW UP VISIT
Chief Complaint
Mrs. Mott is a 57 year old woman who was diagnosed with breast c ancer in April 2018. She was found to have extensive 
bone metastases, adenopathy and hepatic lesions. Tumor was biopsied showing ER positive, PR positive, Her 2 amplified 
breast cancer. Systemic treatment was initiated 5/8/18 with paclitaxel, trastuzumab and pertuzumab. First cycle well 
tolerated. She returns today for consideration of cycle 2.
On-going Treatment  EventsNeurological: Patient reports: no headache, no peripheral neuropathy, no focal weakness, no tremor, no altered consciousness, n
oseizures, no speech impairment, no dizziness.  no paralysis,  nervousness
Vital Signs
Vitals on 5/29/18  12:11:00 PM: Height=66in, Weight=155lb, Pulse=74, SystolicBP=122, DiastolicBP=68  
Ph
ysical 
General:  Patient appears:  well developed and well nourished,  No alopecia noted.  
Eyes: No scleral icterus, and/or pallor. Conjunctiva clear. EOMs intact. Pupils equal and reactive to light. 
Cardi
ovascular:  Heart with regular rate and rhythm. Normal S1 and S2. S3, S4 No gallop. No rubs or clicks. No bruits. Pedal pulses  
present
. 
Chest: Clear 
no rales/rhonchi. No dullness to percussion. No wheezing. Chest wall expansion normal. No chest wall tenderness. No  
stridor. 
Abd
omen: Soft. Non­tender. Non­distended. No palpable masses. No ascites. No hepatosplenomegaly. Bowel sounds present in all 
quadrants.
 No hernia. 
Hematologic/
Lymp
hatic: No cervical lymphadenopathy. No supraclavicular lymphadenopathy. No axillary lymphadenopathy. No inguinal  
lymphadenopathy. No petechiae. No ecchymosis. 
Ski
n: No rashes. No lesions.  Extremities appear normal. No evidence of cyanosis.  No edema.  No clubbing present. 
Neurologic:  Alert and oriented.  Normal speech.  Cranial nerves in tact.  
Genitourinary:  Examination deferred.  
Rectal
: Examination deferred.  
G
ynecological:  Examination deferred.
Laboratory Results
Lab results on 5/29/2018: Sodium=135 mmol/L, Potassium=4.2 mmol/L, CO2=31 mmol/L, Chloride=99 mmol/L, Glucose=84 mg/dL, 
Calcium=9.0 mg/dL, BUN=14 mg/dL, Creat=1.1 mg/dL, Alk Phos=45 U/L, ALT=21 U/L, AST=23 U/L, Total Bili=0.9 mg/dL, Albumin=3.7g 
dL, Total Protein=7.5 g/dL. WBC=4.1 x10E3/uL, RB
C=4.63 x10E6/uL, HGB=9.9 g/dL, HCT=31.4%, MCV=68 fL, MCH=21.4 pg, 
MCHC=31.5 g/dL, RDW=16.1 %, Plat=179 x10E3/uL, ANC=2.8 x10E3/uL, Lymph#=1.0 x10E3/uL, MONO#=0.2  x10E3/uL, BASO#=0.1 
x10E3/uL, EOS#=0.1 x10E3/uL, MONO%=5 %, BASO%=1 %, EOS%=1 %, Neut%=68 %
Imag
ing Results
Radiology results were reviewed and discussed with the patient, including 4/2018-  MRI Brain no metastasis deep white matter changes 
suggestive of inflammatory process. PET/CT - left breast mass; diffuse bone metastases; liver lesions suspicious for metastatic breast 
cancer.
Primary Dx 
198.5 - Secondary malignant neoplasm of bone and bone m
arrow, Diagnosed Apr 2018
174.9 - Malignant neoplasm of breast (female), unspecified site, Diagnosed Apr 2018
Assessment
St
age 4  ER HER2 positive breast cancer with bone and liver metastases. Patient had a negative brain MRI.  Testing of tumor 
demonstrates ER+ PR+. HER2neu equivocal on IHC. FISH positive. Diagnostic data reviewed. CBC results from today  reviewed and 
compared to 5/8/18. Proceed today  with cycle 2  TH plus pertuzumab.  
Recommendation/Plan
Time spent with patient was  25 minutes. Over half the time was spent counseling and coordinating care, which included the  
fol
lowing:
Reviewed with patient  treatment side effects.
Support
ive measures reviewed.
Taxol, Herceptin and Perjeta
Office visit 3 weeks with plans to begin zoledronic acid
All 
questions answered
Page 2 of 2  Electronically signed:DATE May 29, 2018  
TIME 12:41PM  
Shannon Wu, M.D.
